Atrix Laboratories, Inc. has announced that the company has formed a dental division to oversee the global marketing operations for Atrix's proprietary dental products, Atridox(R), Atrisorb(R)-Free Flow and Atrisorb(R)-D. Steve Garrett, DDS, MS has been named president of the new division. Dr. Garrett has been Atrix's vice president of clinical research since 1995 and was responsible for the development and commercialization of the Atridox and Atrisorb products.
Dr. Steve Garrett said, "I am looking forward to working closely with our strategic marketing partners in this new role to promote adoption of these products by the U.S. and worldwide dental communities. Our new U.S. marketing partner, CollaGenex Pharmaceuticals, is highly capable and has a successful track record in the professional dental products business. Outside the U.S., it has been a regulatory challenge to get these innovative dental products approved and marketed in other countries, but we have nearly completed this process in Europe and we anticipate expanded sales opportunities around the world."
David R. Bethune, chairman and chief executive officer at Atrix, commented, "I am pleased to name Dr. Garrett to this new position. Steve is recognized globally as an expert in dental medicine with the understanding and leadership skills necessary to capitalize on this existing asset. In addition to his duties as president of the new dental unit, Dr. Garrett will continue to hold the title of senior vice president and officer at Atrix Laboratories, Inc."
